DGAP-News: MorphoSys AG / Key word(s): Change of Personnel/Miscellaneous Planegg/Munich, Germany, October 30, 2017 Dr. Markus Enzelberger Appointed MorphoSys's Chief Scientific Officer
Dr. Enzelberger joined MorphoSys in 2002 and served in various leadership positions within the Company's R&D organization. Since 2012 he acted as Senior Vice President, Discovery, Alliances and Technologies, taking responsibility for the drug discovery activities for both MorphoSys's proprietary and partnered programs as well as for technology development. Dr. Enzelberger is co-inventor of MorphoSys's proprietary antibody libraries Ylanthia and HuCAL Platinum. He led R&D teams working on multiple discovery programs of the Company's pipeline including guselkumab, developed by Janssen, which recently became the first approved drug based on MorphoSys's antibody technology. Prior to joining MorphoSys, Dr. Enzelberger, a chemist by training, worked at the California Insititute of Technology on the core technology of Fluidigm, a biotechnology company located in California/USA. "Dr. Enzelberger is the perfect person to take over the CSO role at MorphoSys on a permanent basis. Drawing on his vast scientific expertise and experience in the management of antibody technology, research and discovery, he will continue to drive MorphoSys's early-stage research activities with the goal of fueling the Company's R&D pipeline with novel drug candidates in oncology and immunology. We look forward to continuing to work with him," commented Dr. Gerald Möller, Supervisory Board Chairman of MorphoSys AG. "Dr. Sproll is now 17 years with the Company and we would like to thank her wholeheartedly for her invaluable contribution to MorphoSys over the past years, twelve of which she has served as the Company's CSO. Marlies is an incredible authority in the field of protein and antibody science and she has been instrumental in successfully transforming MorphoSys, initially from a young technology company to a global leader in the field of antibody research and development and, then, to a biopharmaceutical company dedicated to developing its own therapeutic antibody portfolio. We are happy that Marlies' tremendous experience will remain available to the Company, and wish her the very best for her new role at MorphoSys," Dr. Möller continued. A picture of Dr. Markus Enzelberger can be downloaded here. About MorphoSys: HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R) and LanthioPep(R) are registered trademarks of the MorphoSys Group. This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned. For more information, please contact: MorphoSys AG Jochen Orlowski Alexandra Goller Tel: +49 (0) 89 / 899 27-404 Additional features: Document: http://n.eqs.com/c/fncls.ssp?u=DAUCEHPVHF Document title: Media Release 30.10.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | MorphoSys AG |
Semmelweisstr. 7 | |
82152 Planegg | |
Germany | |
Phone: | +49 (0)89 899 27-0 |
Fax: | +49 (0)89 899 27-222 |
E-mail: | investors@morphosys.com |
Internet: | www.morphosys.com |
ISIN: | DE0006632003 |
WKN: | 663200 |
Indices: | TecDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange |
End of News | DGAP News Service |